Combination therapy with SCH58500 (p53 adenovirus) and cyclophosphamide in preclinical cancer models

Area of Science:

• Oncology
• Gene Therapy
• Pharmacology

Background:

• SCH58500 (ACN53) is a recombinant adenovirus expressing human p53, demonstrating therapeutic efficacy in preclinical tumor models with nonfunctional p53.
• SCH58500 has shown enhanced activity in combination with various chemotherapeutic agents.
• The combination of SCH58500 with cyclophosphamide has not been previously investigated.

Purpose of the Study:

• To evaluate the anti-tumor efficacy of SCH58500 in combination with cyclophosphamide.
• To compare the efficacy of this combination therapy against single-agent treatment.
• To assess if cyclophosphamide enhances SCH58500's activity in different preclinical cancer models.

Main Methods:

• Testing SCH58500 and cyclophosphamide combination therapy in human tumor xenograft models.
• Evaluating combination therapy in transgenic H-ras mice and FVB mice with syngeneic MidT2-1 tumors.
• Comparing combination therapy outcomes to single-drug treatments and previous combination studies.

Main Results:

• Cyclophosphamide did not enhance SCH58500 activity in three out of four human tumor xenograft models.
• Combination therapy was not superior to single-agent treatment in transgenic H-ras mice and FVB mice.
• This lack of enhancement contrasts with previous findings where SCH58500 combined with other agents showed improved efficacy.

Conclusions:

• The combination of SCH58500 and cyclophosphamide did not demonstrate synergistic anti-tumor effects in the tested preclinical models.
• Further investigation into this specific combination therapy is warranted before considering clinical trials.
• The efficacy of SCH58500 is dependent on the specific chemotherapeutic agent used in combination.